MURRAY HILL, N.J.--(BUSINESS WIRE)--C. R. Bard, Inc. (NYSE: BCR) today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has improved the pass-through payment for the Lutonix® drug-coated balloon (DCB) under the Medicare hospital outpatient prospective payment system. The purpose of the reimbursement is to cover additional cost to U.S. hospitals for treating Medicare beneficiaries with the Lutonix DCB in the outpatient setting. After further review, CMS determined that costs associated with DCBs were not included in existing reimbursement for percutaneous transluminal angioplasty, stenting, or atherectomy procedures. Therefore, CMS is removing the device offset charge from the calculation and will reimburse the full cost of DCBs in these procedures. This reimbursement determination is retroactive to April 1, 2015.
Help employers find you! Check out all the jobs and post your resume.
